Burdened Biopure keeps afloat with cash injection
This article was originally published in Clinica
Executive Summary
The last week has seen Biopure, the troubled blood substitute firm, receive a couple of much-needed boosters. The Cambridge, Massachusetts-based company closed a successful round of financing, netting $10.5m in proceeds after placing 40 million shares with institutional and individual investors. Cash-strapped Biopure had announced earlier in December that it expected its funds to dry up by January 2005 and needed to raise an additional $19m to keep it operational through the coming fiscal year.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.